Weekly Recap: Bio-Rad growth and margin plan and digital PCR expansion

Bio-Rad Laboratories, Inc. Class A (NYSE:BIO) unveiled a multi-year plan to drive growth, margin expansion and stronger free cash flow by leveraging its digital PCR franchise—led by Droplet Digital PCR, a large assay library and new entry-level QX700 units from Stilla—through portfolio discipline a…